Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma

American Journal of Medical Genetics

Volumn 78, Issue 3, 1998, Pages 271-273

  Oriola, Josep ^a   Páramo, Concepción ^b   Halperin, Irene ^a   García Mayor, Ricardo V ^b   Rivera Fillat, Fca ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b Complejo Hospitalario Xeral Cies ^*  (Spain)

Author keywords

ACRS PCR; FMTC; Medullary thyroid carcinoma; RET protooncogene

Indexed keywords

ARTICLE; CALCITONIN BLOOD LEVEL; CODON; DIAGNOSTIC ACCURACY; ENDEMIC DISEASE; EXON; GENE MUTATION; GENOTYPE; HUMAN; MULTIGENE FAMILY; PHENOTYPE; PHEOCHROMOCYTOMA; POINT MUTATION; PRIORITY JOURNAL; PROTO ONCOGENE; THYROID MEDULLARY CARCINOMA;

CARCINOMA, MEDULLARY; CYSTEINE; DNA PRIMERS; DROSOPHILA PROTEINS; EXONS; FEMALE; GENES, DOMINANT; GENETIC SCREENING; GENOTYPE; HUMANS; MALE; MULTIPLE ENDOCRINE NEOPLASIA; PEDIGREE; PHENOTYPE; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; PROTO-ONCOGENES; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 0031802249     PISSN: 01487299     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8628(19980707)78:3<271::AID-AJMG13>3.0.CO;2-C     Document Type: Article

References (25)

1. Boccia LM, Green JS, Joyce C, Eng C, Taylor SAM, Mulligan LM (1997): Mutation of the RET codon 768 is associated with the FMTC phenotype. Clin Genet 51:81-85.
2. Bolino A, Schuffenecker I, Luo Y, Sen M, Silengo M, Tocco T, Chabrier G, Houdent C, Murat A, Schlumberger M, Tourniaire J, Lenoir GM, Romeo G (1995): RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10:2415-2419.
3. Budowle B, Chakraborty R, Giusti AM, Eisenberg AJ, Allen RC (1991): Analysis of the VNTR locus DIS80 by the PCR followed by high-resolution PAGE. Am J Hum Genet 48:137-144.
4. Carlson K, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA, Goodfellow PJ, Donis-Keller H (1994): Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 91:1579-1583.
5. Decker RA, Peacock ML (1997): Update on the profile of multiple endocrine neoplasia type 2a RET mutations: Practical issues and implications for genetic testing. Cancer 80:557-568.
6. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA (1993): Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856.
7. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GFW, Jackson CE, Tunnacliffe A, Ponder BAJ (1994): Point mutation within the thyrosine kinase domain of RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3:237-241.
8. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD, Ponder BAJ (1995): A novel point mutation in the tyrosine kinase domain of the RET protooncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10:509-513.
9. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, Ploos van Amstel HK, Lips CJM, Nishisho I, Takai S-I, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xu F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjöld M, Komminoth P, Hendy G, Gharib H, Thibodeau S, Lacroix A, Frilling A, Ponder BAJ, Mulligan LM (1996): The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET mutation consortium analysis. JAMA 276:1575-1579.
10. Frank-Raue K, Höppner W, Frilling A, Kotzerke J, Dralle H, Haase R, Mann K, Seif F, Kirchner R, Rendl J, Deckart HF, Ritter MM, Hampel R, Klempa J, Scholz GH, Raue F and the German Medullary Thyroid Carcinoma Study Group (1996): Mutations of the RET Proto-oncogene in German multiple endocrine neoplasia families: Relation between genotype and phenotype. J Clin Endocrinol Metab 81:1780-1783.
11. Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PLM, Mulligan LM, Zajac JD, Robinson BG, Eng C (1997): Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 82:3902-3904.
12. Haliassos A, Chomel JC, Tesson L, Baudis M, Kruh J, Kaplan JC, Kitzis A (1989): Modification of enzymatically amplified DNA for the detection of point mutations. Nucleic Acids Res 17:606.
13. Hennessy JF, Wells SA Jr, Ontjes D, Cooper CW (1974): A comparison of pentagastrin injection and calcium infusion as provocative agents for the detection of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 39:487-495.
14. Hofstra RM, Landsvater RM, Cecherini I, Stulp RP, Stelwagen T, Luo Y, Passini B, Hoppener JW, Ploos van Amstel HK, Romeo G, Lips CJ, Buys CH (1994): A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375-376.
15. Hofstra RM, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, Colantuoni V, Buys C (1997): A novel point mutation in the intracellular domain of the RET proto-oncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 82:4176-4178.
16. Hoppener JWM, Lips CJM (1996): RET receptor tyrosine kinase gene mutations: Molecular biological, physiological and clinical aspects. Eur J Clin Invest 26:613-624.
17. Höppner W, Haase R, Ritter M, Frank-Raue K, Raue F (1997): A new hot spot for mutations in the RET proto-oncogene causing MEN 2A. Sixth International Workshop MEN and VHL. Abstract 242, p 111.
18. Landsvater RM, Jansen RPM, Hofstra RMW, Buys C HCM, Lips CJM, Ploos van Amstel HK (1996): Mutation analysis of the RET protooncogene in Dutch families with MEN 2A, MEN 2B and FMTC: Two novel mutations and one de novo mutation for MEN 2A. Hum Genet 97:11-14.
19. Lips CJM, Landsvater RM, Höppener JWM, Geerdink RA, Blijham G, Jansen-Schillhorn Van Veen JM, Van Gils PG, De Wit MJ, Zewald RA, Berends MJH, Beemer FA, Brouwers-Smalbraak JB, Jansen RPM, Ploos Van Amstel HK, Van Vroonhoven TJMV, Vroom TM (1994): Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 331:828-835.
20. Miller SA, Dykes DD, Polesky HF (1988): A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:12-15.
21. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BA (1993): Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460.
22. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JBJ, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H, Neumann H, Thibodeau SN, Ponder B (1994): Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 6:70-74.
23. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJM, Gagel RF, Takai SI, Noll WW, Fink M, Raue F, Lacroix A, Thibodeau SN, Frilling A, Ponder BAJ, Eng C. for the International RET mutation consortium (1995): Genotype-phenotype correlation in multiple endocrine neoplasia type 2: Report of the International RET Mutation Consortium. J Intern Med 238:343-346.
24. Schuffenecker I, Billaud M, Calender A, Chambe B, Ginet N, Calmettes CI, Modigliani E, Lenoir GM and the GETC (1994): RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet 3:1939-1943.
25. Smith DP, Houghton C, Ponder BAJ (1997): Germline mutation of RET codon 883 in two cases of de novo MEM 2B. Oncogene 15:1213-1217.